We can’t show the full text here under this license. Use the link below to read it at the source.
Semaglutide and tirzepatide effects on cardiovascular outcomes in people with overweight or obesity in the real world (STEER)
Semaglutide and tirzepatide effects on heart health in people with overweight or obesity in everyday life
AI simplified
Abstract
10,625 patients were included in each matched cohort, showing that semaglutide was associated with a 29% reduction in the risk of major adverse cardiovascular events compared to tirzepatide.
- Semaglutide was linked to a statistically significant 29% reduction in the risk of revised 3-point major adverse cardiovascular events (rMACE-3).
- A 22% reduction in the risk of revised 5-point major adverse cardiovascular events (rMACE-5) was also observed with semaglutide.
- In a secondary analysis, semaglutide demonstrated a 57% lower risk of rMACE-5 compared to tirzepatide.
- The findings suggest that semaglutide may be more effective than tirzepatide in reducing cardiovascular risks among patients with overweight or obesity and established atherosclerotic cardiovascular disease.
AI simplified
Key numbers
29%
Reduction in rMACE-3 Risk
Hazard ratio of 0.71 for rMACE-3.
22%
Reduction in rMACE-5 Risk
Hazard ratio of 0.78 for rMACE-5.
57%
Per-Protocol rMACE-3 Reduction
Hazard ratio of 0.43 in per-protocol analysis.